Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia

Association ofGSTM1andGSTT1Polymorphism with Lipid Peroxidation in Benign Prostate Hyperplasia and Prostate Cancer: A Pilot Study

(2013) Vivek Kumar et al.   DISEASE MARKERS

Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures

(2011) Stéphane Larré et al.   ASIAN JOURNAL OF ANDROLOGY

Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon

(2011) Sivalokanathan Sarveswaran et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Antioxidant Effects of Lycopene in African American Men with Prostate Cancer or Benign Prostate Hyperplasia: A Randomized, Controlled Trial

(2011) R. B. van Breemen et al.   Cancer Prevention Research

Apoptotic Effects of Genistein, Biochanin-A and Apigenin on LNCaP and PC-3 Cells by p21 through Transcriptional Inhibition of Polo-like Kinase-1

(2011) Young Jin Seo et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Flavocoxid Inhibits Phospholipase A2, Peroxidase Moieties of the Cyclooxygenases (COX), and 5-Lipoxygenase, Modifies COX-2 Gene Expression, and Acts as an Antioxidant

(2011) Bruce P. Burnett et al.   MEDIATORS OF INFLAMMATION

5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity

(2010) AS Fischer et al.   BRITISH JOURNAL OF PHARMACOLOGY

Flavocoxid, a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, reduces pancreatic damage in an experimental model of acute pancreatitis

(2010) F Polito et al.   BRITISH JOURNAL OF PHARMACOLOGY

Guidelines for reporting experiments involving animals: the ARRIVE guidelines

(2010) JC McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Benign prostate hyperplasia: a review of the yearʼs progress from bench to clinic

(2010) Robert F Donnell   CURRENT OPINION IN UROLOGY

Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment

(2010) Cécile Ortholan et al.   EUROPEAN JOURNAL OF CANCER

Male Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia (BPH)

(2010) Claus G. Roehrborn   MEDICAL CLINICS OF NORTH AMERICA

Curcumin-Induced Apoptosis in PC3 Prostate Carcinoma Cells Is Caspase-Independent and Involves Cellular Ceramide Accumulation and Damage to Mitochondria

(2010) Ashley L. Hilchie et al.   NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL

Oxidative Stress in Benign Prostatic Hyperplasia and Prostate Cancer

(2010) Gianna Pace et al.   UROLOGIA INTERNATIONALIS

Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages

(2009) D Altavilla et al.   BRITISH JOURNAL OF PHARMACOLOGY

Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: A comparison study with methylprednisolone

(2009) Sonia Messina et al.   EXPERIMENTAL NEUROLOGY

Chronic inflammation in the pathogenesis of benign prostatic hyperplasia

(2009) B. Fibbi et al.   INTERNATIONAL JOURNAL OF ANDROLOGY

Neoplasms escape selective COX-2 inhibition in an animal model of breast cancer

(2009) M. Barry et al.   IRISH JOURNAL OF MEDICAL SCIENCE

Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2

(2009) L Fegn et al.   JOURNAL OF LARYNGOLOGY AND OTOLOGY

Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy

(2009) Khong Kang et al.   Molecular Cancer

Review: Green Tea Polyphenols in Chemoprevention of Prostate Cancer: Preclinical and Clinical Studies

(2009) Naghma Khan et al.   NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL

PGE2 and LTB4 tissue levels in benign and cancerous prostates

(2008) Stéphane Larré et al.   PROSTAGLANDINS & OTHER LIPID MEDIATORS

Celecoxib for Treatment of Nocturia Caused by Benign Prostatic Hyperplasia: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study

(2008) Siavash Falahatkar et al.   UROLOGY

The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms

(2008) George T. Kedia et al.   WORLD JOURNAL OF UROLOGY

Growth factors in benign prostatic hyperplasia: Basic science implications

(2008) M. Scott Lucia et al.   Current Urology Reports

Prostate growth and inflammation

(2007) Alessandro Sciarra et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY